Erman Akkus, Medical Oncology Fellow at Ankara University, shared a post on X about a recent paper by A. Gueiderikh et al. published in BMC Cancer.
“Pancreatic adenocarcinoma third line systemic treatments: a retrospective cohort study”
Authors: Gueiderikh, A., Tarabay, A., Abdelouahab, M. et al.
“3rd line treatments in pancreatic cancer
- 37% of patients could proceed to 3rd line
- mOFS: 2 mo, mOS:5.5 mo
- Erlotinib and gemcitabine monotherapy -> negative outcomes.”
Source: Erman Akkus/X